The 6 Wall Street analysts covering Generate Biomedicines, Inc. hold a median 12-month price target of $27 — +86.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Generate Biomedicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (36): Smaller than most of the companies we track.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GENB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +86.7% from it.
Of the 15 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $30 |
| 8 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $30 |
| 28 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $25 → $30 |
| 28 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | $20 → $22 |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | $16 → $25 |
| 13 Apr 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 24 Mar 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 24 Mar 2026 | Goldman Sachs | Initiates | Buy | — |
| 24 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 24 Mar 2026 | Morgan Stanley | Initiates | Overweight | — |
| 24 Mar 2026 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GENB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 4% of US stocks
Cheaper than 23% of US stocks
Cheaper than 83% of US stocks
Higher than 7% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 91% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Generate Biomedicines, Inc. has a market value of $1.9B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $32.5M. The latest quarter shrank 37.7% year on year.
Net income over the same four quarters: −$230.0M, a −708.1% net margin.
Diluted earnings per share, trailing twelve months: $−2.74.
Free cash flow in the twelve months to 30 June 2026: −$245.9M.
Trailing P/E: −6.6×; forward P/E: −6.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Generate Biomedicines, Inc. employs 312 people — $104K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Generate Biomedicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Generate Biomedicines announced that members of its management team will present at investor conferences in November.
Why it matters — GENB watchers can note upcoming opportunities to hear from the company’s management team.
Zealand Pharma and Generate Biomedicines entered a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases. Generate will receive $30 million upfront, up to $35 million in early preclinical milestones, nearly $1.2 billion in total milestones, and tiered royalties for two initial programs, with an option to add a third.
Why it matters — The agreement expands Generate’s work with its generative AI platform into obesity and other metabolic diseases and provides for upfront and potential milestone and royalty payments.
Generate Biomedicines and Zealand Pharma entered a collaboration and license agreement to develop protein therapeutics for metabolic diseases. The effort will combine Zealand Pharma’s metabolic health expertise with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions.
Why it matters — The agreement highlights a collaboration applying Generate’s AI platform to the development of potential therapies for metabolic diseases.
The Seeking Alpha article highlights golukibart (GB-0895), Generate Biomedicines’ long-acting asthma biologic targeting twice-yearly dosing and broad phenotype efficacy, with two global Phase 3 trials underway. It also notes Phase 3 costs and potential dilution before topline data as risks, despite a cash runway extending into early 2028.
Why it matters — GENB watchers may track the Phase 3 program’s progress and funding needs as the company seeks to compete in asthma treatment.
Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of GB-5267, an AI-engineered "armored" CAR T cell therapy for ovarian cancer, with the first patient treated. The therapy targets MUC16, a biomarker over-expressed in over 80% of ovarian tumors, and is designed to avoid pre-infusion chemotherapy and its side effects.
Why it matters — This marks the first next-generation cell therapy for ovarian cancer to enter clinical trials, representing a key clinical milestone for Generate Biomedicines' AI-driven cell therapy pipeline.
The 6 Wall Street analysts covering Generate Biomedicines, Inc. have a median 12-month price target of $27, with estimates ranging from $22 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Generate Biomedicines, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Generate Biomedicines, Inc. 1 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Generate Biomedicines, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (36 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +86.7% from the last close, and Ticker Nerd's factor model ranks Generate Biomedicines, Inc. 1 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Generate Biomedicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GENB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $30 over the next 12 months.
Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Generate Biomedicines to Participate in November Investor Conferences". Generate Biomedicines announced that members of its management team will present at investor conferences in November.
Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics. The company’s Generate Platform combines computational design with biological engineering to create medicines across multiple protein-based modalities, including antibodies, enzymes, cytokines, peptides, and cell therapies. Its pipeline includes investigational programs such as GB-0895 for severe asthma, GB-4362, and GB-5267, reflecting its emphasis on developing treatments for complex and hard-to-address diseases. Based in Somerville, Massachusetts, Generate Biomedicines operates at the intersection of artificial intelligence, drug discovery, and therapeutic development, serving as a platform-driven innovator in modern biomedicine.
CEO Mr. Michael T. Nally M.B.A. · 312 employees · United States · https://generatebiomedicines.com
